Melphalan Tillomed (Melphalan)

Melphalan belongs to the alkylating agent class. It attaches an alkyl group to the N7 position of guanine in DNA, creating cross‑links that prevent DNA replication and transcription. This interference triggers cell‑cycle arrest and apoptosis, particularly in fast‑growing cancer cells.

The specific dose of melphalan is individualized by the prescribing oncologist based on the patient’s diagnosis, body surface area, renal function and treatment protocol. Dosage regimens can vary widely, so the prescriber determines the appropriate amount and schedule for each case.

Melphalan is classified as contraindicated during pregnancy because it can cross the placenta and cause fetal toxicity, including birth defects and miscarriage. It is also excreted in breast milk, so breastfeeding is not recommended while receiving treatment. Women of child‑bearing potential should use effective contraception.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Melphalan Tillomed. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Melphalan shares the DNA‑cross‑linking mechanism common to alkylating agents such as cyclophosphamide and busulfan, but it is often preferred for certain hematologic cancers like multiple myeloma because of its potency and clinical experience. Its toxicity profile, especially myelosuppression, may be more pronounced, requiring careful monitoring compared with some alternatives.

Melphalan Tillomed should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. The product must be handled by qualified personnel in a controlled environment, and any reconstituted solution should be used according to the manufacturer’s stability guidelines.

Melphalan Tillomed is administered intravenously by a qualified healthcare professional. The drug is typically diluted in a compatible infusion solution and infused over a prescribed period, which may range from a few minutes to several hours depending on the treatment protocol and patient tolerance.

The most serious risks include severe myelosuppression leading to infection, anemia or bleeding; secondary malignancies such as therapy‑related leukemia; and organ toxicities like pulmonary fibrosis. Patients should be monitored closely for signs of infection, respiratory symptoms and abnormal blood counts throughout therapy.

Melphalan is contraindicated in patients with known hypersensitivity to the drug or other alkylating agents, in pregnant or nursing women, and in individuals with severe bone‑marrow failure or uncontrolled infections. Caution is also advised for patients with significant renal or hepatic impairment, where dose adjustments may be required.